PAI-1 and Diabetes: A Journey From the Bench to the Bedside
Open accessThe DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
D iabetologists have been well awaresince the seminal work ofHimsworth(1) in the 1930s that type 2 (insu-lin resistant) and type 1 (insulin defi-cient) diabetes were distinct entities with different pathophysiological bases. They have been aware for some time that type 2 diabetes is associated with resistance of tissues such as muscle and liver to the biological effects of in-sulin. Furthermore, they knew that type 2 diabetes per se and insulin resistance could both predispose to an increased risk of premature coronary artery dis-ease and particularly the premature oc-currence of myocardial infarction (MI). By contrast, cardiologists came to em-
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Another prominent SASP component, PAI-1, is increased in the circulation and tissues, such as coronary arteries of patients with diabetes (57).”
From Cellular Senescence in Type 2 Diabetes: A Therapeutic Opportunity (2015) · cites this paper as [57]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Randomized Trial of Therapies for Type 2 Diabetes and Coronary Artery Disease
(2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805796 · Cited by 1,939
Writing Committee Members, Greenland, P., Alpert, J. S., Beller, G. A., Benjamin, E. J., Budoff, M. J., Fayad, Z. A., Foster, E., Hlatky, M. A., Hodgson, J. M., et al. (2010) · Circulation · doi:10.1161/cir.0b013e3182051b4c · Cited by 1,873
Hamsten, A., Wiman, B., de Faire, U., & Blombäck, M. (1985) · New England Journal of Medicine · doi:10.1056/nejm198512193132501 · Cited by 1,342
Alessi, M. C., Peiretti, F., Morange, P., Henry, M., Nalbone, G., & Juhan-Vague, I. (1997) · Diabetes · doi:10.2337/diab.46.5.860 · Cited by 615 · cited 1×
“Adipose tissue expresses PAI-1 (23) and may be a particularly important source of PAI-1 in blood in obese subjects.”
BackgroundEhrmann, D. A., Schneider, D. J., Sobel, B. E., Cavaghan, M. K., Imperial, J., Rosenfield, R. L., & Polonsky, K. S. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.7.4069 · Cited by 461
Self-citationVague, P., Juhan-Vague, I., Aillaud, M. F., Badier, C., Viard, R., Alessi, M. C., & Collen, D. (1986) · Metabolism · doi:10.1016/0026-0495(86)90209-x · Cited by 443
Werf, F. V. D., Ludbrook, P. A., Bergmann, S. R., Tiefenbrunn, A. J., Fox, K. A. A., Geest, H. D., Verstraete, M., Collen, D., & Sobel, B. E. (1984) · New England Journal of Medicine · doi:10.1056/nejm198403083101001 · Cited by 358
Self-citationFactors Responsible for Impaired Fibrinolysis in Obese Subjects and NIDDM Patients
McGill, J. B., Schneider, D. J., Arfken, C. L., Lucore, C. L., & Sobel, B. E. (1994) · Diabetes · doi:10.2337/diab.43.1.104 · Cited by 310
Self-citationAlessi, M. C., Juhan-Vague, I., Kooistra, T., Declerck, P. J., & Collen, D. (1988) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1646997 · Cited by 289 · cited 2×
“Triglycerides and their constituents (fatty acids) increase the expression of PAI-1 in HepG2 cells (15).”
BackgroundTissue-type plasminogen activator antigen and plasminogen activator inhibitor in diabetes mellitus.
Auwerx, J., Bouillon, R., Collen, D., & Geboers, J. (1988) · Arteriosclerosis: An Official Journal of the American Heart Association, Inc. · doi:10.1161/01.atv.8.1.68 · Cited by 276 · cited 1×
“Results of studies in vivo linking diabetes and insulin resistance to increased expression of PAI-1dElevated concentrations of PAI-1 have been observed consistently in blood from patients with diabetes, particularly those with type 2 diabetes (17).”
Background
Cited by
Cellular Senescence in Type 2 Diabetes: A Therapeutic Opportunity
Palmer, A. K., Tchkonia, T., LeBrasseur, N. K., Chini, E. N., Xu, M., & Kirkland, J. L. (2015) · Diabetes · doi:10.2337/db14-1820 · Cited by 423
“Another prominent SASP component, PAI-1, is increased in the circulation and tissues, such as coronary arteries of patients with diabetes (57).”
BackgroundHemorrhagic Transformation in Ischemic Stroke and the Role of Inflammation
Spronk, E., Sykes, G., Falcione, S., Munsterman, D., Joy, T., Kamtchum-Tatuene, J., & Jickling, G. C. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.661955 · Cited by 225
Thrombosis and Vascular Inflammation in Diabetes: Mechanisms and Potential Therapeutic Targets
Pechlivani, N., & Ajjan, R. A. (2018) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2018.00001 · Cited by 197
Hypofibrinolysis in diabetes: a therapeutic target for the reduction of cardiovascular risk
Kearney, K., Tomlinson, D., Smith, K., & Ajjan, R. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0515-9 · Cited by 130
“Hormonal (hyperinsulinemia) and metabolic (hyperglycemia and hypertriglyceridemia) derangements, typically found in T2DM patients, seem to have a role in elevated levels of PAI-1 levels in this population [130].”
BackgroundDiabetic Vasculopathy: Molecular Mechanisms and Clinical Insights
Jia, G., Bai, H., Mather, B., Hill, M. A., Jia, G., & Sowers, J. R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25020804 · Cited by 135
“On the one hand, insulin resistance increases plasminogen activator inhibitor-1 (PAI-1) and fibrinogen while decreasing tissue plasminogen activator levels [66].”
BackgroundInfluentialAdipose tissue angiogenesis in obesity
Lemoine, A. Y., Ledoux, S., & Larger, É. (2013) · Thrombosis and Haemostasis · doi:10.1160/th13-01-0073 · Cited by 115
“PAI-1 inhibits the fibrinolytic system, whose role is crucial for vessel destabilisation, angiogenesis initiation and adipogenesis, but also in atherosclerosis (43); but PAI-1 can both positively and negatively regulate angiogenesis depending on dosage (44).”
BackgroundWilliams, K. J., & Wu, X. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.02.004 · Cited by 87
“The development of imbalanced insulin action in endothelium, monocytes, and elsewhere enhances the ERK limb relative to the AKT limb, thereby increasing tissue factor and PAI1 expression.”
BackgroundKonieczyńska, M., Fil, K., Bazanek, M., & Undas, A. (2013) · Thrombosis and Haemostasis · doi:10.1160/th13-07-0566 · Cited by 80
“Plasma PAI-1 has been shown to be increased in patients with type 2 diabetes, contributing to inhibition of fibrinolysis (31, 33).”
BackgroundStress-induced RNA–chromatin interactions promote endothelial dysfunction
Calandrelli, R., Xu, L., Luo, Y., Wu, W., Fan, X., Nguyen, T. C., Chen, C.-J., Sriram, K., Tang, X., Burns, A. B., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18957-w · Cited by 79
Coco, L. D., Vergara, D., Matteis, S. D., Mensa’, E., Sabbatinelli, J., Prattichizzo, F., Bonfigli, A. R., Storci, G., Bravaccini, S., Pirini, F., et al. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8050720 · Cited by 73
“This was consistent with previous studies that described a functional correlation between PAI-1, ferritin, and type II diabetes [41,42].”
ResultSmall molecules inhibitors of plasminogen activator inhibitor-1 – An overview
Rouch, A., Vanucci‐Bacqué, C., Bedos‐Belval, F., & Baltas, M. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.01.010 · Cited by 63
“Due to its involvement in various physiological processes, PAI-1 is also implicated in many pathologies such as vascular thrombosis [25,26], neointimal hyperplasia [27,28], atherosclerosis [29,30], tumor progression [20], metastasis [20], Alzheimer disease [31], obesity [32,33], diabetes [32,34,35] and fibrosis [36,37…”
BackgroundMohamed, H. G., Idris, S. B., Mustafa, M., Ahmed, M. F., Åstrøm, A. N., Mustafa, K. B. E., & Ibrahim, S. O. (2015) · PLoS ONE · doi:10.1371/journal.pone.0127660 · Cited by 53
Coudriet, G. M., Delmastro-Greenwood, M. M., Previte, D. M., Marré, M. L., O’Connor, E., Novak, E. M., Vincent, G., Mollen, K. P., Lee, S., Dong, H. H., et al. (2017) · Antioxidants · doi:10.3390/antiox6040085 · Cited by 56
“PAI-1 is an acute phase protein and primary inhibitor of both tissue-type and urokinasetype plasminogen activators (tPA and uPA)—mediators of fibrinolysis [48,49].”
Zhai, J., Li, Z., Zhou, Y., & Yang, X. (2022) · Journal of Reproductive Immunology · doi:10.1016/j.jri.2022.103490 · Cited by 47
Physiology and pathophysiology of the plasminogen system in the kidney
Svenningsen, P., Hinrichs, G. R., Zachar, R., Ydegaard, R., & Jensen, B. L. (2017) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-017-2014-y · Cited by 49
Sakurai, S., Jojima, T., Iijima, T., Tomaru, T., Usui, I., & Aso, Y. (2020) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2020.107703 · Cited by 40
Ruscica, M., Macchi, C., Giuliani, A., Rizzuto, A. S., Ramini, D., Sbriscia, M., Carugo, S., Bonfigli, A. R., Corsini, A., Olivieri, F., et al. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01948-8 · Cited by 45
“Finally, increased concentrations of PAI-1 in blood are associated with a predisposition toward venous thrombosis and compelling evidence shows markedly increased concentrations of PAI-1 in blood and the arterial wall of individuals with T2DM [55].”
BackgroundHeilbronn, L. K., Campbell, L. V., Xu, A., & Samocha-Bonet, D. (2013) · PLoS ONE · doi:10.1371/journal.pone.0078864 · Cited by 36
“Obese patients with and without type 2 diabetes have elevated levels of PAI-1 as compared to lean individuals and this is closely linked with insulin resistance [13].”
BackgroundTarsitano, M. G., Pandozzi, C., Muscogiuri, G., Sironi, S., Pujia, A., Lenzi, A., & Giannetta, E. (2022) · Nutrients · doi:10.3390/nu14142926 · Cited by 39
Sun, H., Mi, X., Gao, N., Yan, C., & Yu, F. X. (2015) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.15-16606 · Cited by 35
The Association of Acute Phase Proteins in Stress and Inflammation-Induced T2D
Speelman, T., Dale, L., Louw, A., & Verhoog, N. J. D. (2022) · Cells · doi:10.3390/cells11142163 · Cited by 41
Azad, N., Agrawal, L., Emanuele, N., Klein, R., Bahn, G., McCarren, M., Reaven, P. D., Hayward, R. A., Duckworth, W. C., & the VADT Study Group (2013) · Diabetes Care · doi:10.2337/dc13-1193 · Cited by 35
“7 disease (8,9,16) an independent predictor of incidence of diabetes (17), and is associated with insulin resistance (18).”
BackgroundTatsumi, Y., Watanabe, M., Kokubo, Y., Nishimura, K., Higashiyama, A., Okamura, T., Okayama, A., & Miyamoto, Y. (2013) · Journal of Epidemiology · doi:10.2188/jea.je20130004 · Cited by 24
Proteins Altered by Surgical Weight Loss Highlight Biomarkers of Insulin Resistance in the Community
Shah, R. V., Hwang, S., Yeri, A., Tanrıverdi, K., Pico, A. R., Yao, C., Murthy, V. L., Ho, J. E., Vitseva, O. I., Demarco, D., et al. (2018) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.118.311928 · Cited by 29
Luo, X., Jia, R., Yao, Q., Xu, Y., Luo, Z., Luo, X., & Wang, N. (2016) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201500714 · Cited by 30
Garcia, M. D. S., Sung, N., Mullenix, T. M., Dambaeva, S. V., Beaman, K. D., Gilman‐Sachs, A., & Kwak-Kim, J. Y.-H. (2016) · American Journal of Reproductive Immunology · doi:10.1111/aji.12516 · Cited by 32
Wiggenhauser, L. M., & Krøll, J. (2018) · Current Vascular Pharmacology · doi:10.2174/1570161116666181031101413 · Cited by 30
Diabetes Care: “State of the Union”
Cefalu, W. T. (2012) · Diabetes Care · doi:10.2337/dc12-2182 · Cited by 30
“Other contributions, such as the article from Schneider and Sobel (9), offer us perspectives on a “journey” from the laboratory to the clinic that evaluates the fibrinolytic system in relation to the pathogenesis of coronary artery disease and the precipitation of myocardial infarction.”
BackgroundTakizawa, F., Mizutani, S., Ogawa, Y., & Sawada, N. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.02.064 · Cited by 26
Role of altered coagulation-fibrinolytic system in the pathophysiology of diabetic retinopathy
Behl, T., Velpandian, T., & Kotwani, A. (2017) · Vascular Pharmacology · doi:10.1016/j.vph.2017.03.005 · Cited by 26
PAI-1 Inhibition - Another Therapeutic Option for Cardiovascular Protection.
Baluta, M. M., & VINTILA, M. M. (2015) · PubMed Central · Cited by 26
Carbonyl stress in diabetics with acute coronary syndrome
Bora, S., & Adole, P. S. (2021) · Clinica Chimica Acta · doi:10.1016/j.cca.2021.06.002 · Cited by 26
Becic, T., & Studenik, C. R. (2018) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2018.42.2.101 · Cited by 26
“org ment of T2DM [47] and cardiovascular events and mortality [48].”
BackgroundSafdar, N. Z., Kietsiriroje, N., & Ajjan, R. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242015328 · Cited by 23
“Plasminogen activator inhibitor 1 (PAI-1) PAI-1 plasma levels are classically elevated in T2D and insulin-resistant states [77,123].”
BackgroundLalic, K. S., Jotić, A., Rajkovic, N., Singh, S., Stošić, L., Popović, L., Lukić, L., Milicic, T. J., Seferović, J. P., Macesic, M. V., et al. (2015) · International Journal of Endocrinology · doi:10.1155/2015/390185 · Cited by 16
“Moreover, it has been clearly shown that overexpression of PAI-1 in the vessel wall predisposes to the development of vulnerable plaques formation and acute coronary syndromes [2].”
BackgroundInfluentialJotić, A., Milicic, T. J., Sternic, N. C., Kostić, V., Lalic, K. S., Jeremic, V., Mijajlovic, M. D., Lukić, L., Rajkovic, N., Čivčić, M., et al. (2015) · International Journal of Endocrinology · doi:10.1155/2015/934791 · Cited by 15
“Also, obese diabetics had higher PAI-1 levels compared to nondiabetics, implying permanent impaired fibrinolytic activity, which potentiates thrombosis, based on effect of combination of hormonal (hyperinsulinemia) and metabolic (hyperglycemia) changes characteristic for T2D [13, 40].”
BackgroundMethodZaman, A. K. M. T., McLean, D. L., & Sobel, B. E. (2013) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e31829f0c1b · Cited by 15
Self-citationAlsharoh, H., Ismaiel, A., Leucuta, D., Popa, S., & Dumitrascu, D. L. (2022) · Journal of Gastrointestinal and Liver Diseases · doi:10.15403/jgld-4091 · Cited by 14
Lee, H. J., Yeom, J. W., Yun, J. H., Jang, H. B., Yoo, M., Kim, H.-L., Koo, S. K., & Lee, H. (2023) · Journal of Diabetes · doi:10.1111/1753-0407.13429 · Cited by 14
“Increased PAI-1 levels inhibit the action of PAs and induce blood clotting.(10,11) In the setting of insulin resistance and diabetes, a thrombotic milieu is created by an increase in hepatic synthesis of prothrombotic factors, including PAI-1.”
BackgroundDastgheib, S. A., Najafi, F., Shajari, A., Bahrami, R., Asadian, F., Sadeghizadeh‐Yazdi, J., Akbarian, E., Emarati, S. A., & Neámatzadeh, H. (2020) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-020-00675-1 · Cited by 13
“The progress in the knowledge about the role of PAI-1 gene in up regulation of hyperinsulinemia and hyperglycemia have led to several studies have tested a potential association of the PAI-1 4G5G polymorphism with development of DR and DN in diabetic patients [32], but the results were conflict.”
ResultKorbut, A. I., Klimontov, V. V., Орлов, Н. Б., Khotskina, А. S., & Zav’yalov, E. L. (2019) · Bulletin of Experimental Biology and Medicine · doi:10.1007/s10517-019-04519-8 · Cited by 11
Koca, N., Ayar, K., Bal, Ö., & Ersoy, C. (2021) · Minerva Endocrinology · doi:10.23736/s2724-6507.20.03158-2 · Cited by 14
Jansen, H. J., Vervoort, G., van der Graaf, M., Stienstra, R., & Tack, C. J. (2012) · Clinical Endocrinology · doi:10.1111/cen.12105 · Cited by 13
Hashemi, P., & Pezeshki, S. (2021) · Immunopharmacology and Immunotoxicology · doi:10.1080/08923973.2021.1925294 · Cited by 11
“Metformin can also decrease the concentration of PAI-1 and VEGF in patients with hyperinsulinemia [100,101].”
BackgroundPlasminogen Activator Inhibitor-1 and Pericardial Fat in Individuals with Type 2 Diabetes Mellitus
Bayomy, O. F., Rao, A. D., Garg, R., Vaidya, A., Kotin, A. R., Reiber, B. M. M., Nijmeijer, S. C. M., Carli, M. F. D., Jerosch‐Herold, M., Kwong, R. Y. K., et al. (2017) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2017.0031 · Cited by 11
“Individuals with T2DM, compared to age-matched controls, have elevated levels of plasminogen activator inhibitor-1 (PAI-1), which appears to be implicated in the pathophysiology of CVD.(2,3) PAI-1 is a serine proteinase inhibitor(4) and is the main physiological inhibitor of the endogenous fibrinolytic system primaril…”
InfluentialGuru, S., & Aghanashini, S. (2022) · Journal of Periodontology · doi:10.1002/jper.22-0129 · Cited by 10
Matsui, S., Yamane, T., Kobayashi, K., & Oishi, Y. (2014) · Bioscience Biotechnology and Biochemistry · doi:10.1080/09168451.2014.910096 · Cited by 8
Khosravifar, M., Sajadimajd, S., & Bahrami, G. (2022) · Current Molecular Medicine · doi:10.2174/1566524022666220321125548 · Cited by 10
Wirunsawanya, K., Belyea, L., Shikuma, C. M., Watanabe, R. M., Kohorn, L. B., Shiramizu, B. T., Mitchell, B. I., Souza, S. A., Keating, S. M., Norris, P. J., et al. (2017) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2016.0292 · Cited by 6
“PAI-1 is a key regulator of fibrinolysis, which has been found to be associated with coronary artery disease, thrombosis, insulin resistance, and diabetes mellitus.(4,5,8) PAI-1 concentration in chronically stable HIV individuals appears to be higher compared with HIV-negative individuals because of the increased inci…”
BackgroundAnalysis of the inhibition of PAI-1 by metal theaflavin complexes and their degradation products
Jankun, J., Kondray, V., & Skrzypczak‐Jankun, E. (2013) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2013.1308 · Cited by 5
“The inhibition of the elements of plasminogen activator system [urokinase (uPA) and/or tissue plasminogen activator (tPA), as well as plasminogen activator inhibitor-1 (PAI-1)] plays a role in a number of human diseases, including cancer, diabetes, kidney diseases, blood clotting disorders and others (1-5).”
Abdullah, F. E., & Ahmed, S. (2023) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000000915 · Cited by 6
Wu, S., Rau, C., Lu, T., Tzeng, S.-L., Wu, Y.-C., Wu, C., Lin, C.-W., & Hsieh, C. (2015) · Mediators of Inflammation · doi:10.1155/2015/852126 · Cited by 5
Jasmiad, N. B., Ghani, R. B. A., Agarwal, R., Ismail, Z. B., Abdullah, A. A. M., & Idorus, M. Y. (2022) · BMC Ophthalmology · doi:10.1186/s12886-022-02550-4 · Cited by 5
“Although, previous studies have reported as association of serum PAI-1 with obesity and insulin resistance, in the current study we did not observe this association [25].”
ResultGalal, H. M., Abdelhafez, A. T., Sayed, M. M., Gomaa, W. M. S., Tohamy, T. A., Gomaa, A. M. S., & El‐Metwally, T. H. (2024) · Tissue and Cell · doi:10.1016/j.tice.2024.102342 · Cited by 4
Zhang, H., Huang, L., & Li, F. (2025) · Scientific Reports · doi:10.1038/s41598-025-01923-1 · Cited by 5
“On the other hand, hyperinsulinemia stimulates the expression of tissue factors as well as procoagulant activity and thrombin production 29 .”
Shah, A. K., Yadav, B. K., Shah, A. K., Suri, A., & Deo, S. K. (2022) · Journal of Laboratory Physicians · doi:10.1055/s-0042-1750066 · Cited by 7
Basurto, L., Apolinar, L. M., Robledo, A., O’Leary, S., Murillo, C. M., Medina-Ortíz, L. I., Osorio, M. G. M., Zarazua, J., Balcázar‐Hernández, L., & Anda‐Garay, J. C. (2024) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2023.12.004 · Cited by 6
Selleh, P. K., Anto, E. O., Boadu, W. I. O., Sackey, B., Boateng, L. A., Nkansah, C., Nsafoah, F. O., Saasi, A.-R., Mintaah, S., Wiafe, Y. A., et al. (2023) · Health Science Reports · doi:10.1002/hsr2.1297 · Cited by 3
“Metformin not only attenuates the secretion of insulin and enhanced insulin sensitivity but also attenuates the precursors of insulin that have been known to stimulate the expression of PAI‐1 in vivo.(29) Another finding of the present study was that plasma levels of TAFI did not significantly differ between the T2DM…”
ResultMechanisms of Hypercoagulation and Aberrant Clot Lyses in Type 2 Diabetes
Pretorius, E. (2017) · Springer eBooks · doi:10.1007/978-3-319-60324-7_17 · Cited by 3
Tsujimoto, T., & Kajio, H. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.118.011207 · Cited by 4
Sayed, Z. H. E., Ismail, S. M., & Elhakeem, H. (2018) · The Scientific Journal of Al-Azhar Medical Faculty Girls · doi:10.4103/sjamf.sjamf_49_18 · Cited by 2
Fibrinolytic parameters under ischemic stroke with diabetes mellitus combination
Tymoshenko, M. (2019) · Periodicum Biologorum · doi:10.18054/pb.v120i2-3.6703 · Cited by 2
“activator inhibitor 1 (PAI-1), is also a concomitance of type 2 diabetes (3).”
BackgroundAging and Cardiovascular Diseases: The Role of Cellular Senescence
Bozaykut, P. (2019) · Springer eBooks · doi:10.1007/978-981-13-8273-4_10 · Cited by 3
The effects of resistance training on cardiovascular factors and anti-inflammation in diabetic rats
Yoo, J. C., Hwang, J., Choi, J., Ramalingam, M., Jeong, H., Jang, S., Jeong, H., & Kim, D. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e37081 · Cited by 2
“T2DM and CVD may be associated with elevated levels of PAI-1 production and circulation [23,24].”
BackgroundTaha, M., Oliveira, D., Gros, M., Aouiti-Trabelsi, M., & Deghmane, A. (2026) · BMC Infectious Diseases · doi:10.1186/s12879-026-14031-w · Cited by 1
“Besides, its role in the regulation of fibrinolysis, PAI-1 has also been found to be associated with insulin resistance, and diabetes mellitus [45, 46].”
Fibrin formation and lysis in hyperglycaemia – molecular and cellular drivers
Gauer, J. S. (2026) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000932 · Cited by 1
Dynamic changes in RNA-chromatin interactome promote endothelial dysfunctionPreprint
Calandrelli, R., Xu, L., Luo, Y., Wu, W., Fan, X., Nguyen, T. C., Chen, C., Sriram, K., Natarajan, R. D., Chen, Z., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/712950 · Cited by 1
Ahmed, S., Anirban, P., & Lawrence, A. (2020) · SSRN Electronic Journal · doi:10.2139/ssrn.3603361 · Cited by 1
Diabetes Mellitus and Cardiovascular Risk : epidemiology, etiology and intervention
Rautio, A. (2016) · DiVA at Umeå University (Umeå University)
O tecido adiposo como orgão endócrino O papel na insulino-resistência
Esteves, A. L. P. (2013) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · doi:10.34626/2pzg-0j03
Comparison Pai-1 Level in Type 2 Diabetes Mellitus with and Without Diabetic Foot Ulcer
Sholaht, A. D., Gatot, D., Handayani, S., Mardia, A. I., & Syafril, S. (2018) · Sumatera Medical Journal · doi:10.32734/sumej.v1i1.439
İnsülin 100 Yıllık Mucize Hormon
Cerit, E. T., Barlas, T., Atalar, K., Bahçelioğlu, M., Kaplanoğlu, G. T., Seymen, C. M., Erdem, H. B., Ergün, M. A., Demir, Ö., Gülbahar, Ö., et al. (2022) · Akademisyen Kitabevi eBooks · doi:10.37609/akya.871
Basurto, L., Apolinar, L. M., Robledo, A., O’Leary, S., Murillo, C. M., Medina-Ortíz, L. I., Osorio, M. G. M., Zarazua, J., Balcázar‐Hernández, L., & Anda‐Garay, J. C. (2024) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2024.07.007 · Cited by 3
Lipoprotein profiles across a spectrum of insulin signaling
Hwang, M., Shamburek, R. D., Sampson, M. L., Abel, B. S., Lightbourne, M., & Brown, R. J. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.06.003 · Cited by 2
Ruscica, M., Macchi, C., Giuliani, A., Rizzuto, A. S., Ramini, D., Sbriscia, M., Carugo, S., Bonfigli, A. R., Corsini, A., Olivieri, F., et al. (2023) · Figshare · doi:10.6084/m9.figshare.24030918
Simone, I. D., Pocknell, K., Tufaha, S., Konings, J., Roest, M., Wolberg, A. S., Whyte, C. S., Mutch, N. J., de Laat, B., & Huskens, D. (2026) · Research and Practice in Thrombosis and Haemostasis · doi:10.1016/j.rpth.2026.103435
“Congenital PAI-1 deficiency is rare but is associated with a mild-moderate bleeding diathesis [10,11].”
Basu, A., Richardson, L. A., Izuora, K. E., Alman, A. C., & Snell‐Bergeon, J. K. (2026) · Journal of Nutrition · doi:10.1016/j.tjnut.2026.101648
Alshehhi, R., Mousa, M., Lößlein, L., Khader, T. A., van Craenenbroeck, A. V., Ashraf, S. S., Carmeliet, P., & Alsafar, H. (2026) · Molecular Medicine · doi:10.1186/s10020-026-01562-w
“SERPINE1 encodes PAI-1, a key inhibitor of fibrinolysis and ECM degradation that promotes fibrosis (Schneider and Sobel 2012).”
Metadata
- Authors
- Schneider, D. J., & Sobel, B. E.
- Affiliations
- University of Vermont (US)
- Corresponding author
- Schneider, David J.
- ORCID
- Schneider, David J.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2012-09-11
- Volume
- 35
- Issue
- 10
- Pages
- 1961-1967
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3447837
- OpenAlex
- W1974895405
- Cited by
- 78
- References
- 50
- Citations by year
- 2026: 5 · 2025: 2 · 2024: 5 · 2023: 6 · 2022: 9 · 2021: 4 · 2020: 4 · 2019: 6 · 2018: 6 · 2017: 7 · 2016: 4 · 2015: 8 · 2014: 1 · 2013: 9 · 2012: 2
- FWCI
- 4.77
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Disease and Adiposity
- Keywords
- plasminogen activator inhibitor-1, type 2 diabetes, type 1 diabetes, insulin resistance, myocardial infarction, coronary artery disease, cardiovascular risk, thrombosis
- MeSH terms
- Animals, Coronary Artery Bypass, Coronary Artery Disease, Diabetes Mellitus, Type 2, Fibrinolysis, Humans, Insulin, Insulin Resistance, Male, Myocardial Infarction, Obesity, Tissue Plasminogen Activator, Rabbits, Angioplasty, Balloon, Coronary, Randomized Controlled Trials as Topic, Plasminogen Activator Inhibitor 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.